Cited by 345Phytoestrogen effects and researchEstrogen and related hormone effectsFlavonoids in Medical Research

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; none of the 52 sources its claims cite is checked for support yet.

Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: A site-directed mutagenesis study.

Open access
Kao, Y C, Zhou, C, Sherman, M, Laughton, C A, Chen, S·1998·Environmental Health Perspectives

Abstract

Flavone and isoflavone phytoestrogens are plant chemicals and are known to be competitive inhibitors of cytochrome P450 aromatase with respect to the androgen substrate. Aromatase is the enzyme that converts androgen to estrogen; therefore, these plant chemicals are thought to be capable of modifying the estrogen level in women. In this study, the inhibition profiles of four flavones [chrysin (5, 7-dihydroxyflavone), 7,8-dihydroxyflavone, baicalein (5,6,7-trihydroxyflavone), and galangin (3,5,7-trihydroxyflavone)], two isoflavones [genistein (4,5,7-trihydroxyisoflavone) and biochanin A (5,7-dihydroxy-4-methoxyisoflavone)], one flavanone [naringenin (4, 5,7-trihydroxyflavanone)], and one naphthoflavone (alpha-naphthoflavone) on the wild-type and six human aromatase mutants (I133Y, P308F, D309A, T310S, I395F, and I474Y) were determined. In combination with computer modeling, the binding characteristics and the structure requirement for flavone and isoflavone phytoestrogens to inhibit human aromatase were obtained. These compounds were found to bind to the active site of aromatase in an orientation in which rings A and C mimic rings D and C of the androgen substrate, respectively. This study also provides a molecular basis as to why isoflavones are significantly poorer inhibitors of aromatase than flavones.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

This study combined inhibition kinetics, site-directed aromatase mutants, and computer modeling to examine how flavone and isoflavone phytoestrogens bind and inhibit human aromatase. It found that flavones generally inhibit more strongly than isoflavones, with α-naphthoflavone and chrysin most potent, and proposed a binding orientation in which the flavone A and C rings mimic the steroid D and C rings while the C4-keto group faces the heme.

Key findings

  • Among the tested compounds, α-naphthoflavone had the lowest Ki (2.2 ± 0.1 µM), followed by chrysin (2.6 ± 0.1 µM), naringenin (5.1 ± 0.2 µM), 7,8-dihydroxyflavone (10 ± 1 µM), biochanin A (12 ± 5 µM), galangin (95 ± 28 µM), and genistein (123 ± 8 µM); baicalein showed no inhibition up to 50 µM.
  • Isoflavones were poorer aromatase inhibitors than flavones; biochanin A inhibited better than genistein, which the authors attribute to its C4′-methoxy rather than C4′-hydroxy substituent.
  • Mutations altered inhibitor potency in ways that supported the proposed binding pose: for example, chrysin Ki fell from 2.6 ± 0.1 µM in wild type to 0.3 ± 0.1 µM in I133Y, 0.6 ± 0.1 µM in I395F, and 0.06 ± 0.02 µM in I474Y, but rose to 13 ± 3 µM in D309A.
  • Modeling and inhibition profiles indicated that flavones bind with rings A and C mimicking steroid rings D and C, respectively, and with the C4-keto group oriented toward the heme; 5-hydroxy, 3-hydroxy, and C6 substituents reduce binding, while the isoflavone 4′-hydroxy group also weakens aromatase inhibition.

Methods

  • Inhibition kinetics were measured for eight phytoestrogens on wild-type human aromatase and six mutants (I133Y, P308F, D309A, T310S, I395F, I474Y) expressed in Chinese hamster ovary cells, using a ³H₂O release assay with 100 nM radiolabeled androstenedione and Ki values derived from Dixon plots.
  • Mutants were generated by PCR-based site-directed mutagenesis, stably expressed in CHO cells, and confirmed by enzyme activity and western blot or immunoprecipitation analysis.
  • Computer modeling used a previously generated human aromatase homology model; compounds were placed in the active site and energy minimized first with a rigid pocket and then allowing active-site residue movement.

Limitations

  • The paper states that this is an in vitro study and that in vivo effects could differ because of metabolic conversion; cell culture and animal studies were described as initiated but not reported here.
  • The paper states that the biphasic inhibition profiles observed for galangin in wild-type and some mutants are not understood, and that possible interaction with other CHO proteins cannot explain why only some mutant forms showed this pattern.
  • The paper notes that naringenin Ki values may reflect a racemic mixture, so the S-configuration isomer may have lower actual Ki; evident from the text, the conclusions also depend on a homology-based computational model and a limited set of six mutants, and baicalein was not tested against mutants because it did not inhibit wild-type aromatase up to 50 µM.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1289/ehp.9810685

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 of 52 cited sources checked · 0 supported · 0 flagged

  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 19
  • The quote only partly states this claim. 1
33 of 33
  • The paper relies on this without support.

    The molecular basis of phytoestrogen inhibition of aromatase is not known.

    “While phytoestrogens have been reported to be inhibitors of aromatase, the molecular basis of their inhibition of aromatase is not known.”
  • The authors state this as an assumption.

    The active site pocket of aromatase is rigid during initial modeling.

    “assuming that the pocket was rigid.”
  • The authors state this as an assumption.

    Residues within the active site can move to better accommodate inhibitors (induced fit).

    “assuming that residues within the active site can move to better accommodate the inhibitors (induced fit theory of molecular interaction)”
  • The paper relies on this without support.

    The computer model of the aromatase active site accurately represents the enzyme's active site and the binding orientations of the compounds.

    “Our computer modeling has revealed that only the S-configuration isomer can bind to the active site.”
    “Computer modeling suggests that the pocket on the distal helix side may be more compact or rigid so that ring B of chrysin and the two isoflavones have to be held at about the same position.”
  • The paper relies on this without support.

    The inhibition profiles and Ki values measured in the assay directly reflect the binding affinity of the compounds to aromatase.

    “The results obtained from inhibition profile studies indicate that the binding of genistein is improved by conformational changes upon mutations in the region Pro-308 to Thr-310.”
  • The paper relies on this without support.

    The site-directed mutations alter the active site pocket in the intended way without grossly disrupting the enzyme's overall structure.

    “Its binding was also improved by Ile-474 to Tyr, Ile- 133 to Tyr, and Ile-395 to Phe mutations.”
6 of 6

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

  • Genistein's reported ER-binding advantage exceeds the stated range

    Minor

    The stated IC50 values are 2.0 pM for genistein and 33 pM for chrysin. Their ratio is 16.5, outside the stated 5-10-fold range.

    Reported 10 · recomputed 16.5

1 of 1

Citations

Cites

Flagged first, then by citations

Show all 46 references

Cited by

Sorted by citations

See all 345

Metadata

Authors
Kao, Y. C., Zhou, C., Sherman, M., Laughton, C. A., & Chen, S.
Affiliations
Beckman Research Institute (US)
Venue
Environmental Health Perspectives
Published
1998-02
Volume
106
Issue
2
Pages
85-92
ISSN
  • 0091-6765 (ISSN-L)
  • 1552-9924
OpenAlex
W2008151923
Cited by
338
References
46
Citations by year
2026: 5 · 2025: 3 · 2024: 5 · 2023: 9 · 2022: 5 · 2021: 14 · 2020: 11 · 2019: 5 · 2018: 7 · 2017: 11 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 17 · 2012: 10
FWCI
9.12
Type
journal article
Language
en
Open access
Licence
public-domain
Locations
  • Environmental Health Perspectives (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Funders
  • National Cancer Institute (R01CA044735, CA 44735)
  • National Institute of Environmental Health Sciences (ES-08258, R01ES008258)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Phytoestrogen effects and research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Pharmacology (medical) › Flavonoids in Medical Research
Keywords
phytoestrogens, flavones, isoflavones, flavanones, naphthoflavone, competitive inhibition, chrysin, baicalein, galangin, genistein, biochanin A, naringenin, active site binding, structure-activity relationship, estrogen synthesis
MeSH terms
Animals, Aromatase, Binding Sites, Enzyme Inhibitors, Estrogens, Non-Steroidal, Flavonoids, Cricetinae, Isoflavones, Models, Molecular, Plants, Mutagenesis, Site-Directed, CHO Cells, Reverse Transcriptase Polymerase Chain Reaction, Plant Preparations, Aromatase Inhibitors, Phytoestrogens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review